The American Diabetes Assocation’s 83rd Scientific Sessions were held from June 23- 26th. This annual conference brings together researchers and scientists to both present and learn about the latest in […]
What is Glucagon? Glucagon is a hormone that helps the liver release glucose to raise blood glucose levels. It can be administered through injection, auto-injection pen or nasal spray. Glucagon […]
JDRF Canada, in collaboration with CIHR, is thrilled to announce the recipients of the CIHR-JDRF Type 1 Diabetes Screening Research Consortium. This $12 million grant will develop a single nationally […]
The name Garfinkle is synonymous with JDRF Canada. Over 50 years ago, in 1971 and 1973 respectively, Krayna Golfman and Mitch Garfinkle saw their sons, David and Jimmy diagnosed with […]
Low blood sugar, called hypoglycemia, is a real fear for people with type 1 diabetes (T1D). Although there are rescue treatments for it, such as injectable or nasal glucagon (Baqsimi), there are currently no preventive therapies available. Canadian company Zucara Therapeutics, however, may have an answer.
On May 23, 2023 the U.S. Food and Drug Administration (FDA) cleared the iLet® Insulin-Only Bionic Pancreas System for people 6 years of age and older with type 1 diabetes […]
JDRF provides seed funding for highly innovative research with significant potential to accelerate the most promising type 1 diabetes (T1D) research in both cures and approaches to improve disease management. […]
In late April 2023, Helena Gottschling was elected Board Chair for JDRF Canada. Helena Gottschling is a purpose-driven leader who enjoyed a 37-year career with RBC before retiring in 2022. […]
Mental health and psychosocial issues remain an under-researched yet frequent aspect of living with type 1 diabetes (T1D). As part of the JDRF-CIHR Partnership to Defeat Diabetes, JDRF is pleased […]
May is Mental Health Awareness month, a national movement to raise awareness of the importance of mental health, and the structural gaps that exist in accessing treatment and support. There […]
JDRF Canada and all JDRF affiliates are committed to supporting the development of cell replacement therapies that will one day offer cures for type 1 diabetes (T1D). T1D is an […]
In addition to funding critical type 1 diabetes (T1D) clinical trials, a key focus for JDRF is increasing awareness of and participation in trials. All new interventions, from drugs to […]
